← Eichor
Study identifier: NCT07372131 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients

Condition: Bloodstream Infection · Gram Negative Infections · Bacteraemia Caused by Gram-Negative Bacteria  ·  Sponsor: Valeria Cento

PhaseNA
Planned participants172
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic malignancies (such as leukemia or lymphoma) who develop febrile neutropenia and Gram-negative bacteraemia. The main questions it aims to answer are: * Can a personalized antibiotic duration increase the number of days free from anti-Gram-negative therapy within 28 days without compromising patient safety? * How does the duration of antibiotic therapy (short vs. prolonged) affect the rate and modality of gut microbiota reconstitution? Researchers will compare: * Group A (Personalized Duration): Antibiotics are stopped after the patient maintains clinical stability (no fever and stable vital signs) for 72 consecutive hours. * Group B (Standard of Care): Antibiotics are continued for a standard duration, typically at least 10 days, based on current clinical surveys and physician decision. Participants will: * Be randomized to receive either the personalized or the standard duration of antibiotic therapy once a Gram-negative infection is confirmed in the blood. * Be monitored for 28 days to assess for new fever episodes, recurrence of infection, and overall survival. * If participating in the microbiological sub-study, provide biological samples (blood, feces, and rectal swabs) at specific time points (at the onset of fever, at the end of treatment, and …

This description comes directly from the study's public registry record.

Talk to the study team

Valeria Cento, MD, PhD  ·  0282243166  ·  valeria.cento@hunimed.eu

Michele Bartoletti, MD, PhD  ·  0282243568  ·  michele.bartoletti@hunimed.eu

Always discuss trial participation with your own doctor first.

Locations (1)

Microbiology and Virology - IRCCS Humanitas Research HospitalRozzano, Milan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07372131